GlassScriptPhysician profile
Dmitry A Grebenev
NPI 1528003043
$8,433.45
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,891 · 2020: $409 · 2021: $1,641 · 2022: $1,250 · 2023: $1,621 · 2024: $622.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,243 · Education: $0.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,242.59 |
| Education | $0.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Minimed, INC. | $1,858.29 | 2019-2020 | |
| Novo Nordisk INC | $777.50 | 2019-2024 | Ozempic, Rybelsus, Tresiba |
| Sanofi-Aventis U.S. LLC | $614.09 | 2019-2024 | |
| Lilly USA, LLC | $608.18 | 2019-2023 | Jardiance, Mounjaro, Baqsimi |
| Medtronic, INC. | $530.96 | 2021-2024 | Minimed 780g |
| Merck Sharp & Dohme LLC | $433.83 | 2019-2022 | |
| Amgen INC. | $384.26 | 2019-2024 | Evenity, Prolia |
| Dexcom, INC. | $376.03 | 2019-2024 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $327.88 | 2020-2021 | |
| Amarin Pharma, INC. | $225.79 | 2021-2022 | |
| Antares Pharma, INC. | $211.54 | 2019-2023 | Xyosted, Tlando, Nocdurna |
| Cequr Corporation | $201.28 | 2023 | Cequr Simplicity |
| Bayer Healthcare Pharmaceuticals INC. | $187.57 | 2023-2024 | |
| Amneal Pharmaceuticals LLC | $185.98 | 2019-2023 | Unithroid |
| Janssen Pharmaceuticals, INC | $174.22 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $170.82 | 2021-2023 | Tepezza |
| Radius Health, INC. | $162.93 | 2021-2024 | Tymlos |
| Novartis Pharmaceuticals Corporation | $146.68 | 2022-2024 | |
| Abbott Laboratories | $132.41 | 2021-2023 | Freestyle Libre 2 |
| Astrazeneca Pharmaceuticals LP | $115.41 | 2019-2022 | |
| Corcept Therapeutics | $114.51 | 2020 | |
| Insulet Corporation | $109.89 | 2021-2023 | Omnipod |
| Tandem Diabetes Care, INC. | $70.75 | 2023-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Halozyme INC | $69.38 | 2023 | |
| Ibsa Pharma INC. | $54.28 | 2022-2023 | Tirosint, Licart |
| Beta Bionics, INC. | $31.41 | 2024 | Ilet Bionic Pancreas |
| Shire North American Group INC | $26.22 | 2019 | |
| Valeritas, INC. | $25.68 | 2019 | |
| Xeris Pharmaceuticals, INC. | $24.73 | 2024 | Gvoke Hypopen |
| Nevro Corp. | $21.60 | 2024 | Senza |
| Regeneron Healthcare Solutions, INC. | $20.39 | 2019 | |
| Abbvie INC. | $19.68 | 2019 | |
| Tolmar, INC. | $19.28 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dmitry Grebenev listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.